List view / Grid view
In the fourth instalment of EPR's ‘Microbiome therapeutics: microscope to medicine’ series, Emilie Plantamura, Deputy Chief Medical Officer at MaaT Pharma, examines the promising potential of microbiome therapeutics beyond Clostridium difficile infection, particularly in the onco-haematological field.
The first faecal microbiota product to prevent recurrence of Clostridioides difficile infection in adults has been approved by the FDA.
In a new paper, Lumen Bioscience detailed how spirulina can be genetically engineered for to rapidly produce large quantities of biologic drugs.
Collaborating with Google, Lumen Bioscience applied Bayesian black-box optimisation, a machine learning approach, to increase spirulina biomanufacturing productivity.
There is a growing adoption of metabolomics to support drug discovery and development. Metabolomics involves the comprehensive analysis of metabolites in biological specimens. As such, it is commonly used for the discovery and validation of biomarkers that can support critical decisions in the drug development process. In this article, Christopher…
The human gut contains the largest ecosystem of microbial species having complex host-microbiome interactive networks that contribute to our physiology and regulate our immune system. An imbalance in this host-microbiome interaction is associated with disease and the ability to restore or stabilise the network by introducing a rich and diverse…
Ibezapolstat cured all 10 patients of their Clostridioides difficile infections and prevented recurrence for at least 30 days.
GlobalData latest report states that the major drivers of this growth include the projected launch of prophylactic options for the prevention of Clostridium difficile infections...
11 April 2016 | By Victoria White, Digital Content Producer
A current lack of data on outcomes in patients with IBD who have CDI means that appropriate choice of treatment strategy can be unclear...
8 December 2015 | By
MGB-BP-3 is an antibiotic that is being developed for the potential treatment of Clostridium difficile infections...
23 October 2015 | By Victoria White
GlobalData says this increase will be driven by the modest uptake of patent-protected, Clostridium difficile infection-specific antibiotics and the arrival of novel non-antibiotic approaches...
21 September 2015 | By Victoria White
Merck plans to submit new drug applications seeking regulatory approval of bezlotoxumab in the US, EU and Canada in 2015...
21 July 2015 | By Victoria White
The first group of healthy volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3...
28 May 2015 | By Victoria White
Seres Therapeutics has enrolled and dosed the first patient in its Phase 2 clinical study of SER-109 in recurrent CDI in adults...
21 May 2015 | By Victoria White
Data presented from the Clostridium difficile Infection (CDI) Service Evaluation study shows that the adoption pattern of treatment impacts CDI outcomes...
